Clinical trial Recruiting at 1 site Interventional Ages 50 and up

Personalized high-definition transcranial direct current stimulation for posterior cortical atrophy

Official title: Testing Personalized High Definition Transcranial Direct Current Stimulation (HD-tDCS) as a Treatment of Posterior Cortical Atrophy

Run by University of Michigan · NCT07191327 · Data updated 2026-11-12

This trial will test whether personalized HD-tDCS can improve visual and thinking abilities in people with posterior cortical atrophy.

Quick facts

Study typeInterventional
Ages50 Years and up
SexAll
Enrollment50 (estimated)
SponsorUniversity of Michigan
Academic / other
Locations1 site (Ann Arbor, Michigan)
StatusRecruiting
StartedJanuary 28, 2026
Main results expectedJuly 31, 2029
Study endsJuly 31, 2029
Registry record updatedJune 30, 2026
Trial IDNCT07191327 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults with a diagnosis or symptoms consistent with posterior cortical atrophy who are fluent in English, medically compatible with HD-tDCS, and on stable relevant medications.

Probably not a fit

Patients with other primary neurological disorders (e.g., epilepsy, large-vessel stroke, moderate–severe TBI), active major psychiatric illness, recent substance or alcohol abuse, or who are incompatible with HD-tDCS are unlikely to benefit from this protocol.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized, sham-controlled protocol gives participants either real or sham HD-tDCS across eight sessions over four days, followed by an optional open-label phase of real HD-tDCS extending up to 26 weeks. Imaging (fMRI and PET/CT) and standardized memory, visual, and computerized cognitive tests are used before and after treatment to measure change. The approach uses individualized stimulation targeting and compares active stimulation to a placebo-like sham. Remote long-term visits are possible but require a study partner to administer stimulation at home, and participants must meet language and medical compatibility requirements.

Why it matters

Potential benefit: If successful, this could offer a noninvasive option to improve visual processing and cognitive function for people with PCA.

How similar studies have gone: Smaller tDCS studies in related dementia and visual-processing conditions have shown mixed, preliminary results, so personalized HD-tDCS is promising but remains experimental for PCA.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Diagnosis or symptoms consistent with PCA
* Fluent in English
* HD-tDCS compatible
* Stable on relevant medications for at least approximately 4 weeks prior to study enrollment
* If completing any additional, optional, long-term study visits in a remote location (i.e., not our office), a study partner is required in order to administer HD-tDCS. Those choosing to return to our office may have, but are not required to have, a study partner.

Exclusion Criteria:

* Other relevant neurological disease (e.g., epilepsy) or injuries (e.g., large vessel stroke, moderate-severe traumatic brain injury) viewed as primary to deficits since these could interfere with etiologic considerations and confound study results
* Active, relevant psychiatric conditions (e.g., bipolar disorder, schizophrenia) since the symptoms of these conditions may confound study participation.
* A recent (e.g., within the past 2 years) significant history of, or current, alcohol or drug abuse/dependence. Remote history of abuse/dependence is not exclusionary as long as it is not considered to be the primary etiology for visuospatial deficits.
* Women that are lactating/breastfeeding, pregnant, or may potentially be pregnant will be excluded from the study.

Where it's running

  • University of Michigan
    Ann Arbor, Michigan, United States
    Recruiting

Study contacts

  • Principal investigator: Benjamin Hamstead, PhD — University of Michigan
  • Study coordinator: Stephen Schlaefflin, BS
  • Email: schlst@umich.edu
  • Phone: 734-936-7360

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.